Nike is on the clock — its turnaround efforts are taking too long. Our patience is wearing thin. The stock has been a “remarkable loser,” Jim Cramer said Wednesday on CNBC. In a second day of broader market selling, Nike was giving back nearly half its 3.3% gains in the prior session. Shares are down…
Stocks soared to record highs again last week, capping off a banner month for the market. Investor optimism about an end to the Iran-U.S. war, a string of positive corporate earnings reports, and strength in technology stocks led to new records for the S & P 500 and Nasdaq Composite , up over 1% and…
Nvidia is definitely one to watch this week. After reporting an absolute blowout last week, the Club name has traded lower. Early Tuesday, it was looking to bounce off Friday’s close of $215, before some pressure set in. Why does that matter? We know the fundamentals are as strong as ever at the AI chip…
First, welcome to all who have joined us for the first time. Your participation in the CNBC Investing Club means a great deal to us. We aspire to get it right for you, in the same way a wonderful Club member explained this weekend as we gardened together. He couldn’t believe how much he had…
Stock market bulls wrestled back control last week after a brief respite, putting the S & P 500 back on the cusp of another record high. The index has now advanced for eight straight weeks since its Iran wartime bottom on March 30, its longest winning streak since late 2023, when it strung together nine…
Coal could come back. That was my insight, or more, my instinct, after interviewing Kenny Young, the CEO and seven-year veteran of Babcock & Wilcox , the 160-year-old boiler manufacturer turned engineering and construction company. Young wanted to talk about the surging demand for power spurred by the data center boom. So did I. B…
Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it can live up to the hype. Icotyde went to market after the Food and Drug Administration approved it in mid-March for moderate to severe plaque psoriasis. The once-a-day drug is the first…
Late. Late. Late. That’s how I felt when I saw the Roundhill Memory ETF — symbol DRAM, of course — take in more than $5 billion in a month. Super late when I saw it took in $1.1 billion on Thursday alone, all to play what the press is hailing as the memory supercycle. But…
Another superb week for stocks is in the books. The S & P 500 and Nasdaq rallied on Friday to close out the week at a record high as Wall Street celebrated another solid batch of earnings and a strong-but-not-too-strong jobs report, while holding out hope for an end to the hostilities in the Mideast….
I am growing tired of the endless bubble talk about all of the data center spending. It’s obvious from this quarter that the bubble talk has been proven wrong; try getting someone to say that, though. So, who do I think I am to go there? Just an observer. One who believes that this was…
